Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates

• US 7,931,909 B2
• Filed: 05/02/2006
• Issued: 04/26/2011
• Est. Priority Date: 05/10/2005
• Status: Active Grant

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Burke, James A., Hughes, Patrick M., Chang-Lin, Joan-En
• Primary Examiner(s): Hartley; Michael G
• Assistant Examiner(s): Westerberg; Nissa M
• Application Number:
  US11/416,929
• Publication Number:
  US 20060257452A1
• Time in Patent Office: 1,820 Days
• Field of Search: None
• US Class Current: 424/400
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 27/10 for accommodation disorders, e.g. myopia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component which includes an alpha 2 adrenergic receptor agonist that is cleared from the anterior segment of an individual'"'"'s eye to which the material is administered. The alpha 2 adrenergic receptor agonist may have a vitreal half-life greater than about three hours. The present materials are effective in treating an ocular condition(s) that affect the anterior segment of an eye, or the anterior and posterior segment of the eye. The materials are suitable for intravitreal or periocular administration and can provide prolonged drug delivery and therapeutic benefits to patients to which the materials have been administered. The alpha 2 adrenergic receptor agonists can be provided in liquid-containing formulations and/or bioerodible and/or non-bioerodible polymeric implants and microparticles. Methods of making and using the present materials are also described.

Claims

1. An ophthalmically therapeutic material, comprising:

a therapeutic component comprising a therapeutically effective amount of an alpha 2 adrenergic receptor agonist having a structure effective in providing elimination of the agonist from the anterior chamber of an eye to which the agonist is administered.

2. The material of claim 1, further comprising a liquid carrier component associated with the therapeutic component in the form of a composition suitable for administration to a patient by at least one of intravitreal administration and periocular administration.

3. The material of claim 1, wherein the alpha 2 adrenergic receptor agonist is provided in an amount to provide a therapeutic effect selected from the group consisting of neuroprotection, reduction in intraocular pressure, and combinations thereof.

4. The material of claim 1, wherein the alpha 2 adrenergic receptor agonist has a molecular weight greater than the molecular weight of the alpha 2 adrenergic receptor agonist base structure that is eliminated from the posterior segment of an eye of an individual.

5. The material of claim 1, wherein the alpha 2 adrenergic receptor agonist has a structure effective in providing equal elimination rates from the anterior chamber of the eye and the posterior segment of the eye.

6. The material of claim 1, wherein the alpha 2 adrenergic receptor agonist has a structure effective in providing an anterior elimination rate greater than the posterior elimination rate.

7. The material of claim 1, wherein the material is suitable for administration to an eye and delivers the alpha 2 adrenergic receptor agonist to a region of the eye selected from the group consisting of the anterior chamber of the eye, the posterior chamber of the eye, or combinations thereof.

8. The material of claim 1, further comprising an excipient component.

9. The ophthalmically therapeutic material according to claim 1, wherein said alpha 2 adrenergic receptor agonist has a base structure comprising brimonidine.